Bioventix Announcements

Bioventix plc

(“Bioventix” or “the Company”)

Director Dealing

 

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified today that on 29 January 2024 Peter Harrison, Chief Executive Officer of the Company, sold 62,000 ordinary shares of 5 pence each in the Company (“Ordinary Shares”), at a price of 4,200 pence per Ordinary Share (the “Sale”).

 

The Sale was facilitated to enable a new institutional investor to join the share register. Peter Harrison has undertaken not to dispose of any further Ordinary Shares for 12 months.

 

Following the Sale, Peter Harrison has a beneficial interest in 297,088 Ordinary Shares, representing approximately 5.7 per cent. of the issued share capital of the Company.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

 

 

For further information please contact:

Bioventix plc

Peter Harrison

Bruce Hiscock

 

Chief Executive Officer

Chief Financial Officer

Tel: 01252 728 001

 

 

 

Cavendish Capital Markets Limited

Geoff Nash / Simon Hicks

Nigel Birks / Harriet Ward

 

Corporate Finance

Corporate Broking

Tel: 020 7220 0500

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Peter Harrison

2.

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

62,000 Ordinary Shares

4,200 pence

d)

Aggregated information:

 

·     Aggregated volume

 

·     Price

Sale of 62,000 Ordinary Shares at 4,200 pence each

e)

Date of the transaction

29 January 2024

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

Bioventix plc  

(“Bioventix” or “the Company”)  

Director Dealing 

 

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 28 November 2023 that on 27 November 2023 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 17 ordinary shares of 5 pence each in the Company (“Ordinary Shares”), at an average price of 3,977 pence per Ordinary Share (the “Purchase”). The Ordinary Shares were purchased under a dividend reinvestment plan (“DRIP”). 

 

Following the Purchase, Bruce Hiscock has a beneficial interest in 778 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company. 

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details. 

 

For further information please contact: 

Bioventix plc 

Peter Harrison 

 

Chief Executive Officer 

Tel: 01252 728 001 

Cavendish Capital Markets Limited 

Geoff Nash / Simon Hicks 

Nigel Birks / Harriet Ward 

 

Corporate Finance 

ECM 

Tel: 020 7220 0500 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 

 

1 

Details of the person discharging managerial responsibilities / person closely associated 

a) 

Name 

Bruce Hiscock 

2. 

Reason for the Notification 

a) 

Position/status 

Chief Financial Officer 

b) 

Initial notification/Amendment 

Initial notification 

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 

a) 

Name 

Bioventix plc 

b) 

LEI 

213800225MHX7LZQY108 

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

a) 

Description of the Financial instrument, type of instrument 

Ordinary Shares of 5 pence each 

Identification code 

GB00B4QVDF07 

b) 

Nature of the transaction 

Purchase of Ordinary Shares 

c) 

Price(s) and volume(s) 

17 Ordinary Shares 

3,977 pence 

d) 

Aggregated information: 

 

·     Aggregated volume 

 

·     Price 

Purchase of 17 Ordinary Shares at 3,977 pence each 

e) 

Date of the transaction 

27 November 2023 

f) 

Place of the transaction 

London Stock Exchange, AIM Market (XLON) 

 

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

Bioventix plc (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has today posted its Annual Report for the year ended 30 June 2023 together with a Notice of Annual General Meeting (“AGM”) and Form of Proxy to shareholders that have elected to receive documentation in hard copy format. The documents will also be available to download in PDF format below:

30 June 2023 Annual Report

Notice of AGM

Form of Proxy

The Company’s AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG on Thursday 7 December 2023 at 2.00pm.

 

For further information please contact:

Bioventix plc
Peter Harrison


Chief Executive Officer

Tel: 01252 728 001

Cavendish Capital Markets Limited
Geoff Nash/Simon Hicks
Nigel Birks/Harriet Ward


Corporate Finance
ECM

Tel: 020 7220 0500

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

Bioventix plc (BVXP) announces its audited results for the year ended 30 June 2023

Highlights:
• Revenue up 9% to £12.82 million (2022: £11.72 million)
• Profit before tax up 9% to £10.13 million (2022: £9.28 million)
• Cash at year end of £5.7 million (30 June 2022: £6.1 million)
• Second interim dividend of 90p per share (2022: 74p)
• Total dividends 152p per share (2022: 152p)

Click here to download the full report.

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

Next Page »